CD274 and neoplasm: Understanding the mechanism of tumor-promoting PD-L1 expression and signal transduction in TSCC may provide therapeutic opportunities for improving PD-L1 overexpression-induced intratumor immunosuppression and overcoming resistance to PD-1/PD-L1 antibody-targeted therapy [6].